Clinical trials: Infliximab
Crohn's Disease
Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
The purpose of this study is to determine the safety, tolerability, and efficacy of natalizumab in individuals diagnosed with active Crohn's Disease that are not in remission (CDAI greater than/equal to 150) and are currently…
- Trial name
- NCT00055536
- Testing
- natalizumab
- Where
- 18 sites in United States
- Volunteers
- 60 people
- Sponsor
- Biogen
Schizophrenia
Anti-Inflammatory Challenge in Schizophrenia
This study aims to illuminate the biological underpinnings of negative symptoms in schizophrenia-particularly motivational impairments-by probing the link between systemic inflammation and neural activity in reward-related brain…
- Trial name
- NCT05823532
- Testing
- Infliximab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Pyoderma Gangrenosum, Crohn's Disease
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication.
- Conditions
- Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
- Trial name
- NCT00791557
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University Hospitals Cleveland Medical Center
Crohn's Disease
Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy
To compare treatment outcome in patients with Crohn's disease with secondary loss of response to infliximab (i.e. initial good response follow by loss of response) treated according to current standards based only on clinical…
- Trial name
- NCT00851565
- Testing
- Measurement of serum infliximab and anti-infliximab antibodies, Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status
- Where
- 8 sites in Denmark
- Volunteers
- 120 people
- Sponsor
- Copenhagen University Hospital at Herlev
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients
One of the main potential causes of these failures of BP therapy response is the development of Anti-drug Anti-body (ADAb) in some patients.
- Trial name
- ABI-RA (NCT02116504)
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Arthritis, Rheumatoid
The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol
The purpose of the study was to evaluate the ability of a maintenance dosage regimen of infliximab to achieve and sustain at least 40% improvement from baseline in the total joint count in patients with active Rheumatoid…
- Trial name
- NCT00246064
- Testing
- infliximab
- Volunteers
- 210 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Psoriasis, Parapsoriasis
A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis
The purpose of the study is to evaluate the safety and effectiveness of scheduled and as needed treatment of psoriasis with infliximab.
- Trial name
- NCT00106847
- Testing
- Infliximab
- Volunteers
- 683 people
- Sponsor
- Centocor, Inc.
Acute Pancreatitis
Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)
This study evaluates the effectiveness and safety of infliximab in the treatment of acute pancreatitis in adults. A third of participants will receive one single dose of infliximab via infusion, another third will receive a…
- Trial name
- RAPID-I (NCT03684278)
- Testing
- Infusion of 5 mg/kg Infliximab, Infusion of 10 mg/kg Infliximab
- Where
- 14 sites in United Kingdom
- Volunteers
- 240 people
- Sponsor
- University of Liverpool
Rheumatoid Arthritis, Spondyloarthritis
Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital
The purpose of this study is to evaluate the effectiveness of the switch from the original infliximab ( REMICADE®) to its biosimilar (INFLECTRA®) in all the patients at Cochin hospital receiving REMICADE® for either a rheumatic…
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Crohn's Disease, Uveitis
- Trial name
- SIC (NCT02998398)
- Testing
- Switch from REMICADE® to INFLECTRA®
- Where
- France
- Volunteers
- 262 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Checkpoint Inhibitor, Pilot Study
Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study
To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
- Conditions
- Checkpoint Inhibitor, Pilot Study, Diabetes Melletus
- Trial name
- NCT07257068
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Ulcerative Colitis
In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis
Molecular imaging with infliximab antibody with FITC has the potential to predict therapeutic responses to infliximab antibody and can be used for personalized medicine in ulcerative colitis.
- Trial name
- NCT02852850
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong University
Ulcerative Colitis, Thromboembolism
Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
Post-authorization, prospective and unicenter clinical trial, in which patients with UC will be included. The treatment with anti-TNFα (infliximab, adalimumab or golimumab) or JAK-inhibitors (tofacitinib) will be initiated by…
- Trial name
- NCT05313620
- Testing
- Tofacitinib, Infliximab Adalimumab y Golimumab
- Where
- Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Rheumatoid Arthritis
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)
This is the trial to see how our product is similar to remicade by comparing the results of blood samples when co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose and folic acid in rheumatoid…
- Trial name
- NCT01217086
- Testing
- Infliximab
- Where
- South Korea
- Volunteers
- 617 people
- Sponsor
- Celltrion
Psoriasis, Psoriatic-arthritis
PsoBest - The German Psoriasis Registry
Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g.
- Trial name
- NCT01848028
- Where
- Germany
- Volunteers
- 3,500 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Crohn's Disease
Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography
Anti-TNF therapy induces intestinal wall remodeling that correlates with clinical response and can be detected in patients undergoing serial computed tomography enterography (CTE).
- Trial name
- NCT00819663
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Mayo Clinic
Healthy
A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)
In this study, healthy volunteers will receive a single intravenous dose of either PF-06438179 or infliximab (United States) or infliximab (European Union).
- Trial name
- NCT01844804
- Testing
- PF-06438179, Remicade
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Pfizer
Inflammatory Bowel Disease, Crohn's Disease
IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study
Crohn's disease (CD) is a lifelong condition of inflammation in the bowel. CD can affect any part of the gastrointestinal tract from mouth to anus.
- Trial name
- IDeaL (NCT02847884)
- Testing
- Infliximab
- Where
- 2 sites in Canada
- Volunteers
- 28 people
- Sponsor
- University of Alberta
Sarcoidosis
Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis
In severe refractory sarcoidosis not responding to conventional immunosuppressive treatment, the third-line tumor necrosis factor (TNF)-alpha inhibitor infliximab is an alternative.
- Trial name
- TAWIS (NCT05689879)
- Testing
- STOP arm
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lactation
"Drugs in Lactation" Analysis Consortium
Some medications taken by the breastfeeding women are excreted into milk, posing a potential risk of toxicity to the infant. The first line of evidence required for toxicity risk assessment is prediction of drug levels in milk.
- Trial name
- DLAC (NCT02755194)
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 68 people
- Sponsor
- The Hospital for Sick Children
Colitis, Ulcerative, Crohn Disease
A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants
The purpose of this study is to describe treatment patterns associated with first-line and second line biologic use (vedolizumab or other biologic) and to describe the real-world clinical effectiveness of the use (first-line and…
- Trial name
- EVOLVE-IBERIA (NCT03710486)
- Where
- 26 sites in Portugal, Spain
- Volunteers
- 409 people
- Sponsor
- Takeda